(3aS,5aR,8aR,8bS)-2,2,3a,7,7-Pentamethyl-tetrahydro-bis[1,3]dioxolo[4,5-b;4',5'-d]pyran | 32785-91-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧吡喃
• 英文名称: (3aS,5aR,8aR,8bS)-2,2,3a,7,7-Pentamethyl-tetrahydro-bis[1,3]dioxolo[4,5-b;4',5'-d]pyran
• 英文别名: (1R,2S,6S,9R)-4,4,6,11,11-pentamethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecane
• CAS: 32785-91-4
• 化学式: C₁₂H₂₀O₅
• 分子量: 244.288
• InChiKey: PCJIKTNXIPCBPB-XBWDGYHZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-bromo-1-deoxy-2,3:4,5-di-O-isopropylidene-β-D-fructopyranose 生成 (3aS,5aR,8aR,8bS)-2,2,3a,7,7-Pentamethyl-tetrahydro-bis[1,3]dioxolo[4,5-b;4',5'-d]pyran
  参考文献：
  名称：

  FURSTNER, ALOIS;KOGLBAUER, ULRIKE;WEIDMANN, HANS, J. CARBOHYDR. CHEM., 9,(1990) N, C. 561-570

  摘要：

  DOI：

文献信息

• Topiramate compositions and methods of making and using the same
  申请人：REGENTS OF THE UNIVERSITY OF MINNESOTA

  公开号：US11071787B2

  公开（公告）日：2021-07-27

  The present invention is directed to compositions comprising topiramate and a sulfoalkyl ether cyclodextrin, and methods of making and using the same.

  本发明涉及包含托吡酯和磺烷基醚环糊精的组合物，以及制造和使用该组合物的方法。
• Topiramate Compositions and Methods of Making and Using the Same
  申请人：CLOYD James C.

  公开号：US20090239942A1

  公开（公告）日：2009-09-24

  The present invention is directed to compositions comprising topiramate and a sulfoalkyl ether cyclodextrin, and methods of making and using the same.
• TOPIRAMATE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
  申请人：REGENTS OF THE UNIVERSITY OF MINNESOTA

  公开号：US20170043019A1

  公开（公告）日：2017-02-16

  The present invention is directed to compositions comprising topiramate and a sulfoalkyl ether cyclodextrin, and methods of making and using the same.
• Low Dose Topiramate/Phentermine Composition and Methods of Use Thereof
  申请人：Vivus, Inc.

  公开号：US20170151179A1

  公开（公告）日：2017-06-01

  A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
• US9765081B2
  申请人：——

  公开号：US9765081B2

  公开（公告）日：2017-09-19